基于脂质纳米颗粒的多尺度系统性免疫编程用于癌症治疗
Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy.
目前,肿瘤免疫治疗的临床适用范围受到脱靶毒性、实体瘤中的物理屏障以及个性化细胞疗法复杂制造工艺的限制。
英文原题:mRNA: A promising platform for cancer immunotherapy.
信使RNA(mRNA)如今已成为治疗多种人类疾病,尤其是恶性肿瘤的强大工具,备受瞩目,这得益于COVID-19疫情期间采用脂质纳米颗粒技术的mRNA疫苗所取得的显著临床成果。
信使RNA(mRNA)如今备受瞩目,作为治疗多种人类疾病尤其是恶性肿瘤的强大工具,这得益于COVID-19疫情期间采用脂质纳米颗粒技术的mRNA疫苗所取得的显著临床成果。近期令人鼓舞的临床前和临床结果集中体现了mRNA及基于纳米制剂的递送技术的进步,凸显了mRNA在癌症免疫治疗中的巨大潜力。mRNA可以以多种治疗模式应用于癌症免疫治疗,包括癌症疫苗、过继性T细胞疗法、治疗性抗体和免疫调节蛋白。本综述全面概述了基于mRNA的治疗方法的现状与前景,包括众多递送策略和治疗策略。
Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。